Document Detail


Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest.
MedLine Citation:
PMID:  12037229     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: A study was undertaken to investigate whether bronchodilators are associated with less breathlessness at rest and during light exercise in patients with moderate to severe chronic obstructive pulmonary disease (COPD) with resting tidal expiratory flow limitation (EFL; flow limited (FL)) compared with those without EFL (non-flow limited (NFL)). METHODS: Twenty subjects (13 men) of mean (SD) age 65 (8) years (range 43-77) suffering from COPD with forced expiratory volume in 1 second (FEV(1)) 47 (18)% predicted were studied before and after inhalation of salbutamol (400 microg). Routine pulmonary function tests were performed in the seated position at rest. EFL was assessed by the negative expiratory pressure (NEP) method and changes in end expiratory lung volume (EELV) were inferred from variations in inspiratory capacity (IC). Dyspnoea was measured using the Borg scale at rest and at the end of a 6 minute steady state exercise test at 33% of the maximal predicted workload. RESULTS: EFL occurred in 11 patients. Following salbutamol IC did not change in NFL patients but increased by 24% (95% CI 15 to 33) in FL patients (p<0.001). Maximal inspiratory pressure (PImax) improved at EELV from 45 (95% CI 26 to 63) to 55 (95% CI 31 to 79) cm H(2)O (p<0.05) in FL patients after salbutamol but remained unchanged in NFL patients. The workload performed during exercise amounted to 34 (95% CI 27 to 41) and 31 (95% CI 21 to 40) watts (NS) for patients without and with EFL, respectively. After salbutamol, dyspnoea did not change either at rest or during exercise in the NFL patients, but decreased from 0.3 (95% CI -0.1 to 0.8) to 0.1 (95% CI -0.1 to 0.4) at rest (NS) and from 3.7 (95% CI 1.7 to 5.7) to 2.6 (95% CI 1.1 to 4.0) at the end of exercise (p<0.01) in FL patients. CONCLUSIONS: Patients with COPD with EFL may experience less breathlessness after a bronchodilator, at least during light exercise, than those without EFL. This beneficial effect, which is closely related to an increase in IC at rest, occurs even in the absence of a significant improvement in FEV(1) and is associated with a greater PImax.
Authors:
E Boni; L Corda; D Franchini; P Chiroli; G P Damiani; L Pini; V Grassi; C Tantucci
Related Documents :
12735659 - Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone a...
16405199 - Evidence supporting a new rate threshold for multifocal atrial tachycardia.
7982769 - Physiological and neuropsychological effects of theophylline in chronic obstructive pul...
11069799 - Exercise-induced lactate increase in relation to muscle substrates in patients with chr...
22609499 - Pheripheral airway responsiveness to sub-maximal exercise in asymptomatic cigarette smo...
8296259 - Oxygen desaturation and breathlessness during corridor walking in chronic obstructive p...
761339 - Coronary artery spasm during exercise in patients with variant angina.
23029969 - Influence of deep breathing exercise on spontaneous respiratory rate and heart rate var...
11494189 - Back and abdominal muscle function during stabilization exercises.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thorax     Volume:  57     ISSN:  0040-6376     ISO Abbreviation:  Thorax     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-05-30     Completed Date:  2002-07-16     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0417353     Medline TA:  Thorax     Country:  England    
Other Details:
Languages:  eng     Pagination:  528-32     Citation Subset:  IM    
Affiliation:
Cattedra di Medicina I, Università di Brescia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Adult
Aged
Albuterol / therapeutic use*
Bronchodilator Agents / therapeutic use*
Chronic Disease
Dyspnea / etiology*,  physiopathology
Expiratory Reserve Volume / physiology
Female
Forced Expiratory Flow Rates
Forced Expiratory Volume / physiology
Humans
Male
Middle Aged
Pulmonary Disease, Chronic Obstructive / complications,  drug therapy*,  physiopathology
Vital Capacity / physiology
Chemical
Reg. No./Substance:
0/Bronchodilator Agents; 18559-94-9/Albuterol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Suppression of airway hyperresponsiveness induced by ovalbumin sensitisation and RSV infection with ...
Next Document:  Effect of CPAP on intrinsic PEEP, inspiratory effort, and lung volume in severe stable COPD.